KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

• Status: Recruiting
• Trial end date: 2022-02-25
• Target enrollment: 0
• Participant gender: All

Summary

This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyowa Kirin Pharmaceutical Development, Inc.; Kyowa Kirin, Inc.
• Treatments: Antibodies, Monoclonal; Avelumab

Criteria

Inclusion Criteria:

• Subjects may be male or female and must be ≥ 18 years of age; have an ECOG PS of 0 or 1; and a life expectancy of > 3 months in the Investigator's judgment;

• Subjects are able to understand and willing to sign the ICF, according to institutional standards, prior to the initiation of any study related procedures

• Subjects must have histological or cytological evidence of metastatic or advanced urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis that has predominantly transitional cell or urothelial features); and have measurable neoplastic disease according to RECIST v1.1 criteria

• Subjects must have been previously treated with a platinum-based therapy and progressed; OR Been previously treated with platinum based adjuvant or neo-adjuvant therapy and relapsed or progressed; OR

• Be platinum-based chemotherapy intolerant or ineligible; OR

• Have progressed during or after treatment with approved PD-1/PD-L1 inhibitors

• Subjects must have a tumor accessible for fresh biopsy at the baseline visit and for IDO assessment. If current circumstances prohibit the biopsy procedure (e.g., temporary hospital protocol restrictions, regulatory or local authority requirements, etc.) then archived tissue from previous biopsies (fresh frozen tissue < 9 months and formalin fixed-paraffin embedded [FFPE] block of ≤ 24 months) without intervening checkpoint inhibitors can substitute for a fresh baseline biopsy;

• Subjects must be able to swallow the solid (encapsulated) dosage form of KHK2455

Exclusion Criteria:

• Subjects who have been previously treated with avelumab or any IDO1 inhibitor or CTLA-4, PD-1/PD-L1 checkpoint inhibitors; or any investigational immunotherapy including but not limited to anti-cancer vaccines or oncotropic viruses

• Subjects with prior or current liver metastases;

• Subjects with a history of organ transplant or allogeneic bone marrow transplant;

• Subjects with pre-existing uveitis or other known clinically meaningful retinal disorders as determined by a local ophthalmologist